Adaptimmune Quarterly report pursuant to Section 13 or 15(d)

Share-based compensation - Share-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Total share-based compensation expense included in the consolidated statements of operations
Total share-based compensation expense	$ 5,449	$ 2,624	$ 10,783	$ 4,072
Research and development
Total share-based compensation expense included in the consolidated statements of operations
Total share-based compensation expense	2,512	929	4,887	1,907
General and administrative
Total share-based compensation expense included in the consolidated statements of operations
Total share-based compensation expense	$ 2,937	$ 1,695	$ 5,896	$ 2,165